MedImmune’s Respivir
Executive Summary
Will be reviewed by FDA's Blood Products Advisory Committee on first day of Sept. 23-24 meeting. Respivir (respiratory syncytial virus immune globulin intravenous) will be reviewed as a treatment to reduce the incidence of severe RSV in infants with premature gestation and in children with chronic pulmonary disease. The PLA for Respivir (93-0142) was submitted by the Massachusetts Public Health Biologic Labs under a licensing agreement with Gaithersburg, Md.-based MedImmune ("The Pink Sheet" Jan. 11, T&G- 8). Respivir will be copromoted by Lederle under a deal announced in July ("The Pink Sheet" July 19, T&G-11). The meeting will be held at the Holiday Inn Bethesda, Md. beginning at 8:30 a.m. both days.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth